Announcements Trials
Browse Landscape

Phase

Phase NA 22Phase 1/2 3Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Stress Disorders, Post-Traumatic 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Palliative Care × 90 days × Clear all
NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT03652298 2026-03-13

NeuroPrevPTSD

Centre Oscar Lambret

Phase 2 Terminated
19 enrolled
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Prostatic Neoplasms, Stress Disorders, Post-Traumatic, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡